Sorafenib
Advanced Colorectal Carcinoma
Fudan UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
22 Active assets in the Advanced Colorectal Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Regorafenib City of Hope Medical Center | Phase 2 | B |
Irinotecan City of Hope Medical Center | Phase 3 | B |
Compound Kushen injection Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Phase 4 | B |
rc48-adc Fudan University | Phase 2 | B |
Fruquintinib Fudan University | Phase 2 | B |
View all 28 →
Same molecule, other indications
Sorafenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →